Results 81 to 90 of about 349,757 (388)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Understanding the Toxicity Profile of Approved ADCs

Pharmaceutics
Background: Antibody–drug conjugates (ADCs) represent a novel therapeutic class that combines an antibody against a tumor-associated antigen (TAA), a payload, and a linker that binds these two components. Serious adverse events (SAEs), particularly those
Pablo Ballestín, Alfonso López de Sá, Cristina Díaz-Tejeiro, Lucía Paniagua-Herranz, Adrián Sanvicente, Igor López-Cade, Pedro Pérez-Segura, Carlos Alonso-Moreno, Cristina Nieto-Jiménez, Alberto Ocaña   +9 more
doaj   +1 more source

Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate

mAbs, 2021
This study describes the characterization of conjugation sites for a random, lysine conjugated 2-iminothiolane (2-IT) based antibody-drug-conjugate synthesized from an IgG1 antibody and a duocarmycin analog-based payload-linker. Of the 80 putative lysine
Difei Qiu, Yande Huang, Naresh Chennamsetty, Scott A. Miller, Michael Hay   +4 more
doaj   +1 more source

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study [PDF]

, 2023
Omkar Marathe, Ying Cheng, Alexander I. Spira, Erika Hamilton, Maria M. Rubinstein, X. Dong, Li Li, Dongqing Lv, Jingyun Shi, Nashat Gabrail, H. Amin, C. Wu, Zhe Zhu, Yue Qiu, Vivian W. Gu, Xueting Qiu, Rui Shi, Li Liu, Ping Miao, Naoto T. Ueno   +19 more
openalex   +1 more source

Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves [PDF]

, 2015
peer-reviewedBackground There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by
A Menanteau-Horta, A Vila, AR Peters, B Morein, B Morein, Bernadette Earley, BJF Bradshaw, BM Adair, Bryan Markey, C Pilette, CA Siegrist, CX Song, DG Bryson, DP Greenberg, EM Liebler-Tenorio, F Alexis, F Mansoor, Fawad Mansoor, FM Buonaguro, HM Chen, I Vangeel, J Phillips, J Pollock, JE Crowe, Joseph P. Cassidy, JS Salt, K Tahara, KJ Wiechelman, M Garinot, M Higaki, Michael D. Welsh, ML Hans, MS Lee, OV Kavanagh, PE Shewen, PK Smith, PR Wood, RE Brown, RM Zinkernagel, S Lofthouse, Simon Doherty, TG Kimman, YJ Kwon   +42 more
core   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies

Nature Communications, 2018
The nature of the linker is known to affect the efficacy of antibody–drug conjugate (ADC). Here the authors show cetuximab-guided Avidin-Nucleic-Acid-Nanoassemblies to be superior to cetuximab-doxorubicin conjugate, and show its efficacy in KRAS mutant ...
Francesco Roncato, Fatlum Rruga, Elena Porcù, Elisabetta Casarin, Roberto Ronca, Federica Maccarinelli, Nicola Realdon, Giuseppe Basso, Ronen Alon, Giampietro Viola, Margherita Morpurgo   +10 more
doaj   +1 more source

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy

Nature Biotechnology, 2019
We improve the potency of antibody–drug conjugates (ADCs) containing the human epidermal growth factor receptor 2 (HER2)-specific antibody pertuzumab by substantially reducing their affinity for HER2 at acidic endosomal pH relative to near neutral pH ...
Jeffrey C. Kang, Wei Sun, Priyanka Khare, Mostafa Karimi, Xiaoli Wang, Yang Shen, R. Ober, E. S. Ward   +7 more
semanticscholar   +1 more source